Activities

Home  /  Activities
  • This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)". This is a revised version of the report originally posted on January 23, 2018. An error was identified in table 0.1 and table A21, in which the results of the ORR were inputted in reverse for alectinib and crizotinib. This is now corrected in the revised version. Below is the documentation provided by the Joint Assessment authoring team: PTJA03_Alectinib_Final_Assessment_Report-revised_version_Feb_2018 Input_from_manufacturer_on_the_draft_assessment_Alecensa_PTJA03 Project plan_PTJA03_Alectinib_final

  • This is the assessment of the relative effectiveness of "Screening of fetal trisomies 21, 18 and 13 by non invasive prenatal testing". The purpose of the assessment is to evaluate the relative effectiveness and safety of noninvasive prenatal testing (NIPT) for the screening of fetal trisomy 21, trisomy 18 and trisomy 13 in comparison to first trimester combined screening, evaluating the potential benefits and risks of the different  screening pathways. The final version of the assessment was published in February 2018. This is a revised version of the report originally posted on

  • Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard cataract surgery This is the final project plan of the assessment on “Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard cataract surgery” and the comments provided by one manufacturer during a fact check of the draft project plan. Project Plan_OTCA07_FLACS_FINAL Project Plan Draft_ comments form manufacturers_fact check  

  • The final project plan of the assessment on “Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems” and the comments provided by the external experts and the manufacturers are now available. OTJA08_Project_Plan_CGM_and_FGM OTJA08_Compiled_comments_answers_PP_external_experts_manufacturers

  • [vc_row][vc_column][vc_column_text]This is the final project plan of the assessment on “High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer” and the comments provided by an external expert during scoping. Project Plan_HIFU_final Project Plan external reviewer comments and authors' answers[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][/vc_column][/vc_row]

  • [vc_row][vc_column][vc_column_text]Delivering Products and Services Friday, May 25, 2018 Lindner City Plaza; Cologne, Germany You are cordially invited to the 2018 EUnetHTA Forum, Delivering Products and Services. This year’s event will be held on Friday 25th May 2018 at the Lindner City Plaza in Cologne, Germany. With anticipated speakers from across multiple stakeholder groups, regulatory bodies and national organisations, panels will host a wide range of expert opinions. The Forum will also provide the opportunity for stakeholders and representatives from our 82 partner organisations to network, share experiences and exchange information. A draft agenda will be

  • The 1st EUnetHTA Workshop on HTA and MDR/IVDR Regulation will take place on May 29th, (08:45- 17:30) 2018 in Vienna, Austria. Registration is by invitation only. For additional information, please contact: EUnetHTA_MedDevice_Event@hta.lbg.ac.at

  • We are pleased to announce publication of the collaborative assessment OTCA09 "High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer". This is the assessment of the relative effectiveness of high-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer. The purpose of the assessment is to evaluate the relative effectiveness and safety of high-intensity focused ultrasound as primary therapy or as salvage therapy for the treatment of clinically localised or locally relapsed prostate cancer in comparison to deferred treatment strategies (active surveillance, watchful waiting) and/or standard radical treatment

  • EMA-EUnetHTA meeting December 2017 - Final minutes [pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/04/EMA-EUnetHTA-meeting-Dec-2017-minutes-.pdf" title="EMA-EUnetHTA meeting Dec 2017 minutes"]

  • SOURCE Canadian Agency for Drugs and Technologies in Health (CADTH) HALIFAX, April 17, 2018 - CADTH is pleased to announce that Dr. Michelle Mujoomdar is the 2018 recipient of the Dr. Maurice McGregor Award recognizing rising stars in the field of health technology assessment early in their careers. She will accept the award today at a luncheon in Halifax in front of more than 700 people attending the 2018 CADTH Symposium. Dr. Mujoomdar joined CADTH in 2008 after studying at Brock University and Dalhousie University, where she completed her PhD in pharmacology, as

  • This is the final project plan of the assessment on C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs) and the comments provided by external experts during scoping. OTCA12_Final-project-plan.pdf OTCA12_Draft-project-plan_collated-comments-from-external-experts_fact_check_manufacturers.pdf

  • [vc_row][vc_column][vc_column_text]Forum agenda for download [pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/05/2018-05-24-25-EUNETHTA_FORUM-AGENDA.pdf" title="2018-05-24-25 EUNETHTA_FORUM AGENDA"][/vc_column_text][/vc_column][/vc_row]

  • [vc_row][vc_column][vc_column_text]2018-EUnetHTA-Assemby-Forum-Welcome-Guide.pdf [pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/05/FINALCombined1_Optimize_Optimize.pdf" title="FINALCombined(1)_Optimize_Optimize"][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_raw_html]JTNDZGl2JTIwZGF0YS1jb25maWdpZCUzRCUyMjE4ODE1NDUlMkY2MTQ0MzIyNiUyMiUyMHN0eWxlJTNEJTIyd2lkdGglM0ExMjAwcHglM0IlMjBoZWlnaHQlM0E4NDhweCUzQiUyMiUyMGNsYXNzJTNEJTIyaXNzdXVlbWJlZCUyMiUzRSUzQyUyRmRpdiUzRSUwQSUzQ3NjcmlwdCUyMHR5cGUlM0QlMjJ0ZXh0JTJGamF2YXNjcmlwdCUyMiUyMHNyYyUzRCUyMiUyRiUyRmUuaXNzdXUuY29tJTJGZW1iZWQuanMlMjIlMjBhc3luYyUzRCUyMnRydWUlMjIlM0UlM0MlMkZzY3JpcHQlM0U=[/vc_raw_html][/vc_column][/vc_row]

  • [vc_row][vc_column][vc_column_text]HTA reports; Impact Scotland/HIS; HTA Proposal; Interview BEUC; Partner Profiles: Denmark, Norway and Sweden; NCPE Download HERE[/vc_column_text][vc_column_text][pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/05/Spring_2018_Magazine_Digital_FINAL-wecompress.com_.pdf" title="Spring_2018_Magazine_Digital_FINAL (wecompress.com)"][/vc_column_text][vc_raw_html]JTNDZGl2JTIwZGF0YS1jb25maWdpZCUzRCUyMjE4ODE1NDUlMkY2MTcyMjEyMyUyMiUyMHN0eWxlJTNEJTIyd2lkdGglM0E1MDBweCUzQiUyMGhlaWdodCUzQTUwMHB4JTNCJTIyJTIwY2xhc3MlM0QlMjJpc3N1dWVtYmVkJTIyJTNFJTNDJTJGZGl2JTNFJTBBJTNDc2NyaXB0JTIwdHlwZSUzRCUyMnRleHQlMkZqYXZhc2NyaXB0JTIyJTIwc3JjJTNEJTIyJTJGJTJGZS5pc3N1dS5jb20lMkZlbWJlZC5qcyUyMiUyMGFzeW5jJTNEJTIydHJ1ZSUyMiUzRSUzQyUyRnNjcmlwdCUzRQ==[/vc_raw_html][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row]

  • Complete 2018 Forum live stream video, presentations and hashtag commentary from Cologne, Germany now available. https://www.eunethta.eu/about-eunethta/2018-eunethta-forum/

  • Brussels, July 9, 2018 - Registration is now open Programme Registration Venue Programme Please see the draft agenda of the event•••. Registration Registration to the event is available here. To access to this registration page, you should be registered in the European Commission Access System – EULogin. Please note that all registrations need to be confirmed by the organisers. You will receive a notification that your registration has been confirmed. Please do not book travel tickets and accommodation in advance. Venue (map below) Charlemagne Building Alcide de Gasperi room Rue de la Loi 170 Brussels (Belgium)[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_raw_html]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[/vc_raw_html][/vc_column][/vc_row]

  • [vc_row][vc_column][vc_column_text]The first National Implementation report has now been published. The report follows up the first five EUnetHTA assessments to be published. For these assessments, 46 examples of use have been reported, including both use to support assessment procedures and use as part of dissemination to support awareness of HTA for decision making purposes. As well as follow up of the first five JA3 assessments, the report also includes extended follow up about the use of the 15 JA2 assessments, documenting 96 examples of use to support assessment procedures. A copy of the

  • Following on the successful launch of the JA3 procedures for European Network for Health Technology Assessment (EUnetHTA) Early Dialogues (ED) for Pharmaceutical products, EUnetHTA is pleased to announce the future launch of EDs for Medical Devices. The procedure is a single gateway for early dialogues with European HTA bodies on their evidence-generation plans for medical devices. This initiative builds on previous pilots on early dialogues for medical devices including EUnetHTA JA2 and the SEED project financed by the European Commission. The main benefits of the ED procedure include: Streamlined procedure for applicants;

  • Attended or participated in the live web stream of the the 2018 EUnetHTA Forum in Cologne? We'd love to hear from you. Closing July 20.

  • Real-World Evidence in Medicine Development An online introductory course Under the supervision of leading academics involved in the IMI GetReal project, this interactive online course will give an understanding of current techniques, opportunities and challenges for the use of real-world evidence in medicine development. This is an ideal course for anyone who wishes to become familiar with key issues in the area of real-world data and wishes to broaden his/her expertise. Course participants will come from pharmaceutical companies, regulatory authorities, health technology assessment bodies, patients’ organisations, consultancy companies and academia. The course will

  • We are happy to announce that the documentation of the 1st EUnetHTA Workshop on HTA and MDR/IVDR (from 29th May 2018, Vienna) is now available. Please note that the 2nd EUnetHTA Workshop will take place on TUE 28th May 2019 in Vienna. For further information please contact EUnetHTA_MedDevice_Event@hta.lbg.ac.at [pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/07/Workshop1_Documentation_05.07.2018.pdf"]

  • EUnetHTA Joint Production is pleased to announce the launch of the REA for Sotagliflozin for Type 1 diabetes mellitus (PTJA04) For this specific assessment on a medicinal product for Diabetes Type 1, an ‘open call for patient group submission‘ is used. We are seeking for European and national patient organisations to provide an organisational perspective on the questions in English[1]. In all parts of this form the term “patient” refers to anyone living with, or who has lived with, the condition for which the new medicine is indicated. The information provided

  • This is the final project plan of the assessment on robotic surgery in thoracic and visceral indications. Download HERE [pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/07/Project-Plan_OTCA14.pdf" title="Project Plan_OTCA14"]

  • [vc_row][vc_column][vc_column_text]This is the final project plan of the assessment on Stool DNA testing for early detection of colorectal cancer. Download Final Project Plan HERE Download summary of comments received from external review, including the authors’ answers HERE [pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/07/OTJA10_Project-Plan__final.pdf" title="OTJA10_Project Plan__final"][/vc_column_text][/vc_column][/vc_row]

  • We are pleased to announce that the joint rapid assessment on “Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin” is available. The health technologies assessed include rtCGM systems and FGM systems as personal, stand­alone medical devices for patients with diabetes mellitus type 1 and type 2 (T1DM and T2DM), including adults, children, and patients with gestational DM treated with insulin, either through insulin pump therapy (CSII) or multiple daily insulin injections (MDII). Professional (retrospective) devices are not

  • The final project plan of the assessment on “Bioresorbable Stents in cardiovascular indications (coronary artery disease)” and the comments provided by the external experts and the manufacturers are now available. OTCA16 Project Plan HERE OTCA16 External Expert and Manufacturer Comments HERE

  • EUnetHTA Magazine – Summer 2018 HERE HTA Proposal: Is It Lights Out?; HTA reports; Impact: Lithuania; Interview: EURORDIS; Partner Profile: Poland; Non-Duplication: What’s in it for us? [pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/09/summer_2018_magazine_digital_FINAL-1.pdf" title="summer_2018_magazine_digital_FINAL"]

  • "HTA cooperation produces and will produce very tangible benefits not only for patients, but also improve the quality and sustainability of health systems when Europe needs them most."  [vc_row][vc_column][vc_single_image image="15600" img_size="large"][vc_column_text] [pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/09/Summer_2018_Magazine-2-Photos-Sidebar-and-1-Column.pdf" title="Summer_2018_Magazine - 2 Photos, Sidebar, and 1 Column"][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row]

  • HTA proposal: update; HTA reports; Impact: Italy; Interview: EP Rapporteur: Soledad Cabezón Ruiz MEP; Partner Profile: AIFA; Senior Science Officer: Giovanni Tafuri; working together: HTA Network Stakeholder Pool Downloadable PDF HERE [pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/10/Fall_2018_Magazine-2.pdf" title="Fall_2018_Magazine (2)"]

  • ​We are pleased to announce that the collaborative rapid assessment on "Femtosecond laser-assisted cataract surgery (FLACS) for the treatment of age-related cataract" is available. The health technology assessed a computer-controlled laser system to complete various steps of cataract surgery. The objective of this rapid assessment was to evaluate the effectiveness, safety and procedural time of FLACS compared to the standard manual technique for cataract surgery in patients affected by age-related cataract. A structured approach for rating the importance of effectiveness and safety outcomes was carried out, which informed the systematic review

  • Assistant Project Manager Place: Diemen, Netherlands Contract duration: 2 years Hours per week: 36 Monthly salary: €2,631 - € 4,229 Salary level: scale 10 Level: bachelor Respond before: 12 November to vacancies_eunethta@zinl.nl Job Number: 2018054436 Placement date: 29 October 2018 Employment: Temporary employment Job description Description of functions / tasks The Assistant Project Manager is responsible for coordinating and managing individual assignments. Joint Assessments for pharmaceuticals with an external team of clinical researchers. The Assistant Project Manager is accountable that assigned project deliverables are produced and delivered with EUnetHTA methods, processes and quality standards. The Assistant Project Manager: supports the Project Manager in the management of

  • ​EUnetHTA publishes the EUnetHTA Prioritisation List (EPL) Find the EPL HERE The EPL expresses the identified significant interest of national HTA bodies in relation to individual compounds as presented in the list. By pro-actively selecting those topics in direct collaboration with national bodies, EUnetHTA strives to increase implementation of Joint Assessments qualitatively and quantitatively at the national level. This is one of the key elements of Joint Action 3. The Heads of HTA Agencies of the countries represented in the EUnetHTA Executive Board (ExB) have agreed to take a more proactive approach in

  • The final project plan of the assessment on "Custom-made or customisable 3D printed implants and cutting guides versus non-3D printed standard implants and cutting guides for improving outcome in patients undergoing knee, maxillofacial, or cranial surgery" and the comments provided by the external experts and the manufacturers are now available. OTCA11 Project Plan HERE OTCA11 External Expert and Manufacturer Comments HERE 

  • Minutes of 5 July 2018 EMA/EUnetHTA meeting [pdf-embedder url="https://www.eunethta.eu/wp-content/uploads/2018/11/Minutes-of-the-EMAEUnetHTA-meeting-5-July-2018.pdf" title="Minutes of the EMAEUnetHTA meeting - 5 July 2018"]

  • Implementation Report - November 2018 Appendix: Case study on joint REA to inform economic evaluation - interview summaries Find all implementation reports HERE Find statistical graphics and usage maps HERE [video width="1920" height="1080" mp4="https://www.eunethta.eu/wp-content/uploads/2018/12/9c57bcf0ec20b2ecc4119ee7dfb6ef55-1.mp4" poster="https://www.eunethta.eu/wp-content/uploads/2018/12/AAAAAANational-Uptake-and-Case-Studies-–-EUnetHTA.png" autoplay="true"][/video]

  • The final project plan of the assessment OTCA19 on “Screening for osteoporosis in the general population” and the comments provided by external experts are now available. OTCA19 Project Plan HERE OTCA19 External Expert Comments HERE

  • We are pleased to announce that the collaborative rapid assessment, OTCA06, on “TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) FOR THE TREATMENT OF PATIENTS AT INTERMEDIATE SURGICAL RISK” is available. The health technology assessed is a bioprothesis in the aortic valve deployed using a catheter. The objective of this assessment was to evaluate the relative effectiveness and safety of this technology in contrast to traditional open-heart surgery. Below is the documentation provided by the assessment authoring team: OTCA06 TAVI FOR THE TREATMENT OFPATIENTS AT INTERMEDIATE SURGICAL RISK- FINAL FINAL comments from external reviewers and manufacturers FINAL-Project-Plan-WP4-CA-TAVI